Oct. 2 at 11:08 PM
$NAGE Roth analyst Sean McGoean on September on October 1 also reiterated his buy opinion and Price target of
$23 for Nage.Shorts took advantage of NMN ruling change by FDA which short term has hurt the stock but we have a superior product in NR and also new product money makers in Niagen plus iv’s and recent self injections alternatives.Excellent time to build a position if you have never bought into Niagen Biosciences before the next earnings release in early November.If you already have a position and have excess cash a good time to perhaps dollar cost average!
